Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

References

  1. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17(5): 1474–81

    PubMed  CAS  Google Scholar 

  2. Lønning PE, Lien E. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Hematol 1995; 21: 158–93

    Article  PubMed  Google Scholar 

  3. Lønning PE, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988; 35: 685–710

    Article  PubMed  Google Scholar 

  4. Rose C, Freue M, Kjaer M, et al. An open, comparative randomized trial comparing formestane vs oral megestrol acetate as a second-line therapy in postmenopausal advanced breast cancer patients [abstract PP-8-4]. 7th EORTC Breast Cancer Working Conference; Bordeaux, France 1996 Sep 11-13

    Google Scholar 

  5. Thürlimann B, Castiglione M, HsuSchmitz SF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 1997; 33(7): 1017–24

    Article  PubMed  Google Scholar 

  6. Buzdar AU, Smith R, Vogel C, et al. Fadrozole HCL (CG-S-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Results of two randomized double blind controlled multiinstitutional trials. Cancer 1996; 77(12): 2503–13

    Article  PubMed  CAS  Google Scholar 

  7. Pérez-Carrión R, Candel VA, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5: S19–24

    Article  PubMed  Google Scholar 

  8. Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 1996; 7(5): 465–9

    Article  PubMed  CAS  Google Scholar 

  9. Thürlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer -prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996; 7(5): 471–9

    Article  PubMed  Google Scholar 

  10. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83(6): 1142–52

    Article  PubMed  CAS  Google Scholar 

  11. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16(2): 453–61

    PubMed  CAS  Google Scholar 

  12. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998; 9(6): 639–45

    Article  PubMed  CAS  Google Scholar 

  13. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18(22): 3748–57

    PubMed  CAS  Google Scholar 

  14. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000; 18: 1399–411

    PubMed  CAS  Google Scholar 

  15. MillaSantos A, Milla L, Rallo L, et al. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 2001; 65(2): 119–24

    Article  CAS  Google Scholar 

  16. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18(22): 3758–67

    PubMed  CAS  Google Scholar 

  17. Bonneterre J, Buzdar A, Nabholtz J-M, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92(9): 2247–58

    Article  PubMed  CAS  Google Scholar 

  18. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19(14): 3357–66

    PubMed  CAS  Google Scholar 

  19. Dirix L, Piccart MJ, Lohrish C, et al. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 2001; 20: 29a

    Google Scholar 

  20. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596–606

    PubMed  CAS  Google Scholar 

  21. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12(11): 1527–32

    Article  PubMed  CAS  Google Scholar 

  22. Baum M, Buzdar AU, Cuzick J, et al. Atac Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breat cancer: first results of the ATAC randomised trial. Lancet 2002; 359(9324): 2131–9

    Article  PubMed  CAS  Google Scholar 

  23. Lønning PE. Aromatase inhibitors and inactivators in breast cancer therapy. Drugs Aging 2002; 19(4): 277–98

    Article  PubMed  Google Scholar 

  24. MacNeill FA, Jones AL, Jacobs S, et al. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992; 66: 692–7

    Article  PubMed  CAS  Google Scholar 

  25. Lønning PE, Jacobs S, Jones A, et al. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991; 63: 789–93

    Article  PubMed  Google Scholar 

  26. MacNeill FA, Jacobs S, Dowsett M, et al. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother Pharmacol 1995; 36: 249–54

    Article  PubMed  CAS  Google Scholar 

  27. Jones AL, MacNeill F, Jacobs S, et al. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992; 28A: 1712–6

    Article  PubMed  CAS  Google Scholar 

  28. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74: 1286–91

    Article  PubMed  CAS  Google Scholar 

  29. Geisler J, Haynes B, Anker G, et al. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer natients evaluated in a randomized, cross-over-de-signed study. J Clin Oncol 2002; 20: 751–7

    Article  PubMed  CAS  Google Scholar 

  30. Dowsett M, Jones A, Johnston SRD, et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511–5

    PubMed  CAS  Google Scholar 

  31. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998; 4: 2089–93

    PubMed  CAS  Google Scholar 

  32. Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 2002; 21: 34a, 131

    Google Scholar 

  33. Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 1989; 16: 83–93

    Article  PubMed  CAS  Google Scholar 

  34. Murray R, Pitt P. Aromatase inhibition with 4-OH-androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995; 35: 249–53

    Article  PubMed  CAS  Google Scholar 

  35. Geisler J, Johannessen DC, Anker G, et al. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. Eur J Cancer 1996; 32A: 789–92

    Article  PubMed  CAS  Google Scholar 

  36. Thürlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer 1997; 33(11): 1767–73

    Article  PubMed  Google Scholar 

  37. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane (Aromasin®) in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18: 2234–44

    PubMed  Google Scholar 

  38. Carlini P, Frassoldati A, DeMarco S, et al. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? Ann Oncol 2001; 12(11): 1539–43

    Article  PubMed  CAS  Google Scholar 

  39. Harper Wynne C, Coombes RC. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur J Cancer 1999; 35(5): 744–6

    Article  PubMed  CAS  Google Scholar 

  40. Lønning PE. Cross-resistance to different aromatase inhibitors in breast cancer treatment. Endocr Relat Cancer 1999; 6: 251–7

    Article  PubMed  Google Scholar 

  41. Lønning PE, Kragh LE, Erikstein B, et al. The potential for aromatase inhibition in breast cancer prevention. Clin Cancer Res 2001; 7: 4423s–8s

    PubMed  Google Scholar 

  42. Lien EA, Wester K, Lønning PE, et al. Distribution of tamoxifen and metabolites into brain tissue and brain métastases in breast cancer patients. Br J Cancer 1991; 63: 641–5

    Article  PubMed  CAS  Google Scholar 

  43. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991; 51: 4837–44

    PubMed  CAS  Google Scholar 

  44. Decensi A, Gandini S, Guerrieri Gonzaga A, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 1999; 17(9): 2633–8

    PubMed  CAS  Google Scholar 

  45. Lønning PE. Pharmacology of new aromatase inhibitors. Breast 1996; 5: 202–8

    Article  Google Scholar 

  46. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000; 1 Suppl. 1: s9–sl4

    Article  PubMed  Google Scholar 

  47. Reed MJ, Lai LC, Owen AM, et al. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res 1990; 50: 193–6

    PubMed  CAS  Google Scholar 

  48. Santen RJ, Santner S, Davis B, et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978: 47:1257–65

    Article  PubMed  CAS  Google Scholar 

  49. Jacobs S, Lønning PE, Haynes B, et al. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhib 1991; 4: 315–25

    Article  PubMed  CAS  Google Scholar 

  50. MacNeill FA, Jacobs S, Lønning PE, et al. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. Br J Cancer 1994; 69: 1171–5

    Article  PubMed  CAS  Google Scholar 

  51. Masamura S, Santner SJ, Heitjan DF, et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995; 80: 2918–25

    Article  PubMed  CAS  Google Scholar 

  52. Chen S, Zhou D, Okubo T, et al. Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 1999; 6: 149–56

    Article  PubMed  CAS  Google Scholar 

  53. de Jong PC, van de Ven J, Nortier HWR, et al. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 1997; 57: 2109–11

    PubMed  Google Scholar 

  54. Miller WR, Telford J, Love C, et al. Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. Breast 1998; 7: 273–6

    Article  Google Scholar 

  55. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001; 7: 1230–6

    PubMed  CAS  Google Scholar 

  56. Schanche J-S, Lønning PE, Ueland PM, et al. Determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma by reversed-phase liquid chromatography. Ther Drug Monit 1984; 6: 221–6

    Article  PubMed  CAS  Google Scholar 

  57. Murray FT, Santner S, Samojlik E, et al. Serum aminoglutethimide levels; studies of serum half-life, clearance and patient compliance. J Clin Pharmacol 1979; 19: 704–11

    PubMed  CAS  Google Scholar 

  58. Dowsett M, Goss PE, Powles TJ, et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 1987; 47: 1957–61

    PubMed  CAS  Google Scholar 

  59. Dowsett M, Cunningham DC, Stein RC, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989; 49: 1306–12

    PubMed  CAS  Google Scholar 

  60. Aboul Enein HY, Ali I, Gubitz G, et al. HPLC enantiomeric resolution of novel aromatase inhibitors on cellulose- and amylose-based chiral stationary phases under reversed phase mode. Chirality 2000; 12(10): 727–33

    Article  PubMed  CAS  Google Scholar 

  61. Aboul Enein HY, Ali I, Schmid MG, et al. Chiral resolution of two potential aromatase inhibitors on cellulose tris (4-methyl benzoate) and cellulose tris (3,5-dimethylphenyl carbamate) chiral stationary phases. Anal Lett 2001; 34(7): 1107–15

    Article  CAS  Google Scholar 

  62. Lønning PE. Dose response evaluation: use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. Clin Pharmacokinet 1993; 25: 1–5

    Article  PubMed  Google Scholar 

  63. Adam AM, Bradbrook ID, Rogers HJ. High-performance liquid Chromatographic assay for simultaneous estimation of aminoglutethimide and acethylamidoglutethimide in biological fluids. Cancer Chemother Pharmacol 1985; 15: 176–8

    Article  PubMed  CAS  Google Scholar 

  64. Menge G, Dubois JP. Determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma by high-performance liquid chromatography. J Chromatogr 1984; 310: 431–7

    Article  PubMed  CAS  Google Scholar 

  65. Robinson BA, Cornell FN. Liquid-chromatographic determination of aminoglutethimide in plasma. Clin Chem 1983; 29(6): 1104–8

    PubMed  CAS  Google Scholar 

  66. Coombes RC, Foster AB, Harland SJ, et al. Polymorphically acetylated aminoglutethimide in humans. Br J Cancer 1982; 46: 340–5

    Article  PubMed  CAS  Google Scholar 

  67. Sirtori CR, DeFabiani E, Caruso D, et al. Single dose pharmacokinetics of aminoglutethimide by a rapid SIM methodology. Int J Clin Pharmacol Ther Toxicol 1988; 26(8): 380–4

    PubMed  CAS  Google Scholar 

  68. Aboul-Enein HY, Islam MR. Direct liquid Chromatographic resolution of racemic aminoglutethimide and its acetylated metabolite using a chiral alphal-acid glycoprotein column. J Chromatogr Sci 1988; 26: 616–9

    PubMed  CAS  Google Scholar 

  69. Lønning PE, Schanche JS, Kvinnsland S, et al. Single-dose and steady-state pharmacokinetics of aminoglutethimide. Clin Pharmacokinet 1985; 10: 353–64

    Article  PubMed  Google Scholar 

  70. Nicholls PJ. Pharmacokinetic and balance studies of aminoglutethimide in animals and man. Roy Soc Med, Int Congr Symp Series 1982; 53: 23–4

    Google Scholar 

  71. Appelgren L-E, Brittebo E, Carlstrøm K, et al. Distribution and metabolism of 14C-labelled aminoglutethimide in mice [abstract]. 2nd Scandinavian Breast Cancer Symposium; 1985 May 23–24; Bergen, Norway

    Google Scholar 

  72. Cash R, Brough AJ, Cohen MNP, et al. Aminoglutethimide (Elipten-Ciba) is an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab 1967; 27: 1239–48

    Article  PubMed  CAS  Google Scholar 

  73. Coombes RC, Jarman M, Harland S, et al. Aminoglutethimide: metabolism and effects on steroid synthesis in vivo. J Endocrinology 1980; 87: 31–2

    Google Scholar 

  74. Egger H, Bartlett F, Itterly W, et al. Metabolism of aminoglutethimide in the rat. Drug Metab Disp 1982; 10(4): 405–12

    CAS  Google Scholar 

  75. Foster AB, Griggs LJ, Howe I, et al. Metabolism of aminoglutethimide in humans. Drug Metab Disp 1984; 12(4): 511–6

    CAS  Google Scholar 

  76. Jarman M, Foster AB, Goss PE, et al. Metabolism of aminoglutethimide in humans: identification of hydroxylami-noglutethimide as a induced metabolite. Biomed Mass Spec 1983; 10(11): 620–5

    Article  CAS  Google Scholar 

  77. Adam AM, Rogers HJ, Amiel SA, et al. The effect of acetylator phenotype on the disposition of aminoglutethimide. Br J Clin Pharmacol 1984; 28: 495–505

    Article  Google Scholar 

  78. Murray M, Cantrill E, Farrell GC. Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. J Pharmacol Exp Ther 1993; 265: 477–81

    PubMed  CAS  Google Scholar 

  79. Lønning PE. Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. Cancer Chemother Pharmacol 1990; 26: 241–4

    Article  PubMed  Google Scholar 

  80. Lien EA, Anker G, Lønning PE, et al. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 1990; 50: 5851–7

    PubMed  CAS  Google Scholar 

  81. Deijk WAV, Blijham GH, Mellink WAM, et al. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. Cancer Treat Rep 1985; 69(1): 85–90

    PubMed  Google Scholar 

  82. Lundgren S, Lønning PE, Aakvaag A, et al. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in post-menopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 1990; 27: 101–5

    Article  PubMed  CAS  Google Scholar 

  83. Smith IE, Harris AL, Morgan M, et al. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 1982; 42 Suppl. 8: 3430s–3s

    PubMed  CAS  Google Scholar 

  84. Corkery J, Leonard RCF, Henderson IC, et al. Tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res 1982; 42 Suppl. 8: 3409s–14s

    PubMed  CAS  Google Scholar 

  85. Milsted R, Habeshaw T, Kaye S, et al. A randomized trial of tamoxifen versus tamoxifen with aminoglutethimide in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 1985; 14: 272–3

    Article  PubMed  CAS  Google Scholar 

  86. Ingle JN, Green SJ, Ahmann DL, et al. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide; trial II:aminoglutethimide in patients with prior tamoxifen exposure. Cancer Res 1982; 42 (8 Suppl.): s3461–7

    Google Scholar 

  87. Alonso-Munoz MC, González MBO, Beltran-Fabregat M, et al. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminglutethimide in advanced postmenopausal breast cancer. Oncology 1988; 45: 350–3

    Article  PubMed  CAS  Google Scholar 

  88. Powles TJ, Gordon C, Coombes RC. Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamosifen used alone. Cancer Res 1982; 42 (8 Suppl.): 3458s–60s

    PubMed  CAS  Google Scholar 

  89. Hardy JR, Powles TJ, Judson IR, et al. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. Eur J Cancer 1990; 26: 824–7

    Article  PubMed  CAS  Google Scholar 

  90. Khubieh J, Aherne GW, Chakraborty J. Radioimmunoassay of the anticancer agent 4-hydroxy-androstenedione in body fluids. J Steroid Biochem 1990; 35: 377–82

    Article  PubMed  CAS  Google Scholar 

  91. Guarna A, Moneti G, Prucher D, et al. Quantitative determination of 4-hydroxy-androstene-3,17-dione (4-OHA), a potent aromatase inhibitor, in human plasma, using isotope dilution mass spectrometry. J Steroid Biochem 1989; 32: 699–702

    Article  PubMed  CAS  Google Scholar 

  92. Poon GK, Jarman M, Rowlands MG, et al. Determination of 4-hydroxyandrost-4-ene-3,17-dione metabolism in breast cancer patients using high-performance liquid chromatographymass spectrometry. J Chromatogr 1991; 565: 75–88

    Article  PubMed  CAS  Google Scholar 

  93. Goss PE, Jarman M, Wilkinson JR, et al. Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo: identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat. J. Steroid Biochem 1986; 24: 619–22

    Article  PubMed  CAS  Google Scholar 

  94. Lønning PE, Geisler J, Johannessen DC, et al. Pharmacokinetics and metabolism of formestane in breast cancer patients. J Steroid Biochem Mol Biol 2001; 77(1): 39–47

    Article  PubMed  Google Scholar 

  95. Dowsett M, Lloyd P. Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. Cancer Chemother Pharmacol 1990; 27: 67–71

    Article  PubMed  CAS  Google Scholar 

  96. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia (PA): Lea and Febiger, 1980

  97. Reed MJ, Aherne GW, Ghilchik MW, et al. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissue. Int J Cancer 1991; 49: 562–5

    Article  PubMed  CAS  Google Scholar 

  98. Ackermann R, Kaiser G. Determination of the new aromatase inhibitor CGS 16949 in biological fluids by capillary gas chromatography/mass spectrometry. Biomed Environ Mass Spectrom 1989; 18(8): 558–62

    Article  PubMed  CAS  Google Scholar 

  99. Kochak GM, Mangat S, Mulagha MT, et al. The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. J Clin Endocrinol Metab 1990; 71(5): 1349–55

    Article  PubMed  CAS  Google Scholar 

  100. Kochak G, Choi R, Entwistle E. Dose proportionality and population characteristics of oral fadrozole hydrochloride and aromatase inhibitor in postmenopausal women. Pharm Res 1993; 10(2): 1760–4

    Article  PubMed  CAS  Google Scholar 

  101. Choi R, Sun J, Kochak G. The effect of food on the relative bioavailability of fadrozole hydrochloride. Biopharm Drug Dispos 1993; 14: 779–84

    Article  PubMed  CAS  Google Scholar 

  102. Yuan J, Wang PQ, Ge SR, et al. Pharmacokinetics of anastrozole in Chinese male volunteers. Acta Pharmacol Sin 2001; 22(6): 573–6

    PubMed  CAS  Google Scholar 

  103. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30: 103–11

    Article  PubMed  CAS  Google Scholar 

  104. Yates RA, Dowsett M, Fisher GV, et al. Arimidex (ZD 1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996; 73: 543–8

    Article  PubMed  CAS  Google Scholar 

  105. Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 1997; 25(5): 598–602

    PubMed  CAS  Google Scholar 

  106. St Peter J, Thyrum P, Yeh C, et al. Lack of effect of anastrozole, an aromatase inhibitor, on antipyrine pharmacokinetics in postmenopausal women [abstract pII-27]. Clin Pharmacol Ther 1997; 61(2): 172

    Google Scholar 

  107. Yates RA, Wong J, Sciberling M, et al. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 2001; 51(5): 429–35

    Article  PubMed  CAS  Google Scholar 

  108. Dowsett M, Tobias JS, Howell A, et al. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br J Cancer 1999; 79(2): 311–15

    Article  PubMed  CAS  Google Scholar 

  109. Baum M, Dowsett M, Coibion M, et al. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial. Br J Cancer 2001; 85(3): 317–24

    Article  Google Scholar 

  110. Pfister CU, Duval M, Godbillon J, et al. Development, application and comparison of an enzyme immunoassay and a high-performance liquid chromatography method for the determination of the aromatase inhibitor CGS 20 267 in biological fluids. J Pharm Sci 1994; 83(4): 520–4

    Article  PubMed  CAS  Google Scholar 

  111. Marfit F, Pineau V, Sioufi A, et al. High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection. J Chromatogr 1996; 683: 251–8

    Article  Google Scholar 

  112. Sioufi A, Gauducheau N, Pineau V, et al. Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos 1997; 18(9): 779–89

    Article  PubMed  CAS  Google Scholar 

  113. Sioufi A, Sandrenan N, Godbillon J, et al. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5mg single oral administration. Biopharm Drug Disp 1997; 18: 489–97

    Article  CAS  Google Scholar 

  114. Pfister C, Dowsett M, Iveson T, et al. Pharmacokinetics of new aromatase inhibitor CGS 20267. Eur J Drug Metab Pharmacokinet 1993; 18 Suppl.: 117

    Google Scholar 

  115. Pfister CU, Martoni A, Zamagni C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients. Biopharm Drug Dispos 2001; 22(5): 191–7

    Article  PubMed  CAS  Google Scholar 

  116. Colussi DM, Parisot CY, Lefevre GY. Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor. J Clin Pharmacol 1998; 38(8): 727–35

    PubMed  CAS  Google Scholar 

  117. Wirz B, Valles B, Parkinson A, et al. CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole (Femara®). In: Proceedings of 7th North American ISSX Meeting; 1996. p. 359

    Google Scholar 

  118. Ingle JN, Suman VJ, Jordan VC, et al. Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer. Endocr Relat Cancer 1999; 6: 265–69

    Article  PubMed  CAS  Google Scholar 

  119. Dowsett M, Pfister C, Johnston SRD, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999; 5: 2338–43

    PubMed  CAS  Google Scholar 

  120. Breda M, Pianezzola E, Benedetti MS. Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1993; 620: 225–31

    Article  PubMed  CAS  Google Scholar 

  121. Persiani S, Broutin F, Cicioni P, et al. Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay. Eur J Pharm Sci 1996; 4(6): 331–40

    Article  CAS  Google Scholar 

  122. Cenacchi V, Baratte S, Cicioni P, et al. LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format. J Pharmaceut Biomed Anal 2000; 22(3): 451–60

    Article  CAS  Google Scholar 

  123. Allievi C, Zugnoni P, Benedetti MS, et al. Determination of plasma-levels of exemestane (FCE-24304), a new irreversible aromatase inhibitor, using thermospray liquid-chromatography mass-spectrometry. J Mass Spectrom 1995; 30(5): 693–97

    Article  CAS  Google Scholar 

  124. Cocchiara G, Allievi C, Berardi A, et al. Urinary metabolism of exemestane, a new aromatase inhibitor, in rat, dog, monkey and human volunteers. J Endocrinol Invest 1994; 17 Suppl. 1: 78

    Google Scholar 

  125. Evans TRJ, Salle ED, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992; 52: 5933–39

    PubMed  CAS  Google Scholar 

  126. Spinelli R, Jannuzzo MG, Poggesi I, et al. Pharmacokinetics (PK) of Aromasin® (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). Eur J Cancer 1999; 35: S295, Abstract 1185

    Article  Google Scholar 

  127. Persiani S, Poggesi I, Cicioni P, et al. Pharmacokinetics of repeated low-doses of exemestane (1, 2.5, 5, and 10 mg) in postmenopausal healthy volunteers. Eur J Cancer 1995; 031A: S198, Abstract 952

    Article  Google Scholar 

  128. Jannuzzo MG, Spinelli R, Poggesi I, et al. Inhibition of CYP3A4 does not influence Aromasin® (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV). Eur J Cancer 1999; 35: S294, Abstract 1184

    Article  Google Scholar 

  129. Corry JF, Lønning PE. Systemic therapy in breast cancer: efficacy and cost utility. Pharmacoeconomics 1994; 5: 198–212

    Article  PubMed  CAS  Google Scholar 

  130. Clarke M, Collins R, Davies C, et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351(9114): 1451–67

    Article  Google Scholar 

  131. Abe O, Abe R, Enomoto K, et al. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352(9132): 930–42

    Article  Google Scholar 

  132. Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 2001; 91(3): 484–9

    Article  PubMed  CAS  Google Scholar 

  133. Dranitsaris G, Leung P, Mather J, et al. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anti Cancer Drug 2000; 11(7): 591–601

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The work of the author cited in this paper was supported by the Norwegian Cancer Society. In addition, the author and his group have received research funding on different projects as well as acting as consultants to all the major companies involved in development of aromatase inhibition, (Astra-Zeneca, Novartis and Pfizer).

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Oncology, University of Bergen, Haukeland University Hospital, Bergen, N-5021, Norway

    Per E. Lønning

Authors
  1. Per E. Lønning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Per E. Lønning.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lønning, P.E. Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators. Clin Pharmacokinet 42, 619–631 (2003). https://doi.org/10.2165/00003088-200342070-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200342070-00002

Keywords

Search

Navigation